The Alliance of Angels Innovation Fund
Investing Together in the Next Generation of Innovation
The Alliance of Angels Innovation Fund is a member-led investment program backing high-potential companies across the Pacific Northwest and beyond.
The Alliance of Angels Innovation Fund is a member-led investment program backing high-potential companies across the Pacific Northwest and beyond.
About Us
About the Fund
The AoA Innovation Fund program raises a new fund each year for its members. Each fund invests in 12–15 companies over its life, providing members with diversified exposure to early-stage innovation.
One Member. One Vote.
This is a member-led fund, where all investment decisions are determined by member vote.
Identification
Voting
Investment
Members identify prospective companies, conduct group due diligence and write an investment recommendation.
Recommended companies are presented to the fund members – approval requires 75% Yes vs. No, with a 50% quorum.
When we invest we stay in contact with the company and help them syndicate their round with other investors.
One member, one vote – voting power is not tied to the amount invested.
Investment
Deal Flow and Investment Focus
We leverage the established Alliance of Angels screening process, reviewing hundreds of deals each year.
While most investments come through AoA, the fund may also invest in companies outside the standard AoA process.
Geographic Focus
Primarily Pacific Northwest companies (~70%), with openness to strong opportunities across the U.S. and Canada.
Sector Focus
Sector agnostic — investments are driven by the strength of the deal and founding team.
Expenses
The Innovation Fund operates with exceptionally low expenses due to its volunteer Administrative Team.
Approximately 1.5% annual expenses
No carried interest
This structure is significantly lower than the traditional
2% management fee + 20% carry
charged by most venture funds
Who the Fund Is For
Built for New and Experienced Angels
The AoA Innovation Fund is designed to
Help new investors get started in angel investing
Innovation Fund Portfolio
Search Less. Discover More
3DBioFibR manufactures biopolymer fibers for medical, defense, and textile applications using patented dry-spinning tech.
Abacus develops therapeutic vaccines to treat cancer and chronic viral infections that cause cancer.
Operator of a material science company producing renewable, biodegradable plastics from algae for applications like footwear and surfboards.
Ampd is the fastest, simplest, and most powerful way to launch and maximize Google Ads to marketplaces such as Amazon or Walmart.
Anuncia develops CSF Management/Neurocritical Care therapeutic & monitoring devices for noninvasive at-home use.
Aurenar is improving stroke outcomes and reducing hospital stays/costs with an easy-to-use non-invasive ear stimulation device that activates the body's naturally healing vagal nerve response--with validated clinical results from a recent randomized controlled clinical study.
CorRen is eliminating preventable amputations by bringing reimbursed, specialist-grade PAD testing to primary care.
%20(1).svg)
%20(1).svg)
Cyrus Biotechnology is a pre-clinical-stage AI-driven therapeutics company with an internal pipeline of novel biologics primarily in autoimmune indications.
Ecellix has developed silicon anodes that empower battery makers to shatter limits: high energy, low cost & long life.
Enosemi's semiconductor designs will power the next generation of photonic products for connectivity, computing, sensing, mixed reality, medtech, biotech, and beyond. Note: Enosemi had a successful exit in mid 2025, producing a return for both IF2 and IF4.
Our vision is to build an environment of technology to serve the airport of the future with the goal of increasing safety, efficiency, and to capture service revenue on 100M+ movements at airports each year.
%20(1).svg)
Fitnescity is a consumer health platform that provides easy access to tests and personalized analytics.
Glidance is developing Glide, a personal robot to help blind individuals navigate independently using AI and robotics.
Healionics provides safer, more reliable means of bloodstream access for dialysis in patients with kidney failure.
To become the first line on the table therapy in treating peripheral vascular occlusions by developing a solution aimed at rapid reperfusion without the need for surgery or thrombolytic drug therapies.